While CCR5 inhibitors can be of tremendous benefit to those infected with the CCR5-tropic stain of HIV, our data suggests that blocking the RANTES pathway could negatively influence ongoing immune responses to other persisting infections. The gene discussed is CCL5; the disease is infection.